Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11
- Stem cells
- Drug Discovery
- Technical Know How
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28042
IPSCIO Record ID: 5858
Cardio Vascu-Grow Human Fibroblast Growth Factor-1 treat patients with advanced atherosclerotic disease of their coronary arteries. This treatment, which regenerates new blood vessels in the hearts of these patients. Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoproteins (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoproteins (HDL), (see apoA-1 Milano).
Issued US Patents
1. U.S. 6,268,178 entitled â€œPhage-Dependent Super-Production of Biologically Active Protein and Peptides;â€ and
2. U.S. 6,642,026 entitled â€œMethod of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.â€
3. U.S. 6,773,899 entitled â€œPhage-Dependent Super-Production of Biologically Active Protein and Peptidesâ€;
4. U.S. 6,794,162, entitled â€œPhage-Dependent Super-Production of Biologically Active Protein and Peptides;â€
Pending US Patent Applications 1.. U.S. 10/649,480 entitled â€œMethod of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis;â€ published as US Patent Application No. US 2004/0115769
IPSCIO Record ID: 3533
The patents relate to certain gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia.
The Licensor intellectual property and research involves gene therapy technologies.
IPSCIO Record ID: 273380
— practice under the Patent Rights
— make, have made, use, lease, import, export and/or sell Licensed Products,
— sell, use and/or practice Licensed Services.
The University grants a non-exclusive license to use Know-how for the Field of Use in the territory to
— make, have made, use, lease and/or sell Licensed Products
— sell, use and/or practice Licensed Services.
The Phase II candidate and all other drugs in the portfolio are designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. All have a dual mechanism of action of inhibiting the creation of reactive oxygen radicals and concurrently providing nitric oxide in the failing heart. The therapeutic target is the ryanodine receptor, the ion channel in the heart that provides the calcium necessary for the heart to beat. The investigational drugs are believed to improve calcium cycling in the heart by acting on the ryanodine receptor to significantly improve the efficiency of heart contractility.
The drug portfolio is to develop and commercialize certain of Licensee's proprietary cardiovascular drugs to treat heart failure.
IPSCIO Record ID: 306186
(a) develop, use, demonstrate, sell, offer for sale, market, distribute, and promote Products in the Territory for use in the Field, exclusively,
(b) import Products into the Territory for use in the Field; exclusively;
(c) test and conduct independent Phase 3 clinical studies/trials on or Products in in the Territory, exclusively, and,
(d) manufacture, have manufactured, the Products solely in mainland China solely for use in the Territory and in the Field, non-exclusively.
Compound means Ad5FGF-4, alferminogene tadenovec, an angiogenic gene therapeutic, and natural evolutions thereof.
Product shall mean any biopharmaceutical product containing the Compound, alone or in combination with one or more other active pharmaceutical ingredients, in any dosage form or formulation, including any lyophilized forms thereof.
The initial medical indication will be for the treatment of patients with refractory angina due to ischemic heart disease.
Ischemic heart disease is a condition of recurring chest pain or discomfort that occurs when a part of the heart does not receive enough blood. This condition occurs most often during exertion or excitement, when the heart requires greater blood flow.
IPSCIO Record ID: 29074
IPSCIO Record ID: 29073
IPSCIO Record ID: 104737
IPSCIO Record ID: 368507
U.S. Patent 6,525,078 B1 dated February 24, 2003 entitled â€œCompound for the Treatment of Athreosclerotic-Thrombotic Pathological Conditions.
Atherosclerosis is thickening or hardening of the arteries caused by a buildup of plaque in the inner lining of an artery.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system. Blood clotting, also known as coagulation, is the body's first line of defense against bleeding.
Coronary disease (MCD) is the narrowing of the small blood vessels that branch off the coronary arteries and send oxygen-rich blood to the heart muscle. This decreases the amount of blood that goes to the heart muscle, which leads to chest pain (angina).
IPSCIO Record ID: 3467
Researchers have demonstrated that a deficiency of BH4 can disrupt NO synthesis, resulting in a loss of normal endothelial NO production. This loss of endothelial NO production, commonly referred to as endothelial dysfunction, has been associated with many cardiovascular diseases, including hypertension, diabetic vascular disease, peripheral arterial disease, coronary arterial disease and pulmonary hypertension, and has been shown to be a strong predictor of cardiovascular adverse events in a number of clinical studies.
IPSCIO Record ID: 530